As Omega Diagnostics Group plc & Roxi Petroleum plc Rally, Should You Sell Or Buy?

Omega Diagnostics Group (LON:ODX) plc and Roxi Petroleum plc (LON:RXP) are both rising today, but the latter could be a better choice, argues this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Omega Diagnostics (LSE: ODX) is up 10% today on the back of positive news for Visitect CD4, a testing kit at a development stage that is now more likely to deliver on its promises — meanwhile, confidence was also boosted by encouraging progress on allergy development. 

Similarly, Roxi Petroleum (LSE: RXP) is roaring back in early trade, with its shares gaining almost 20% of value. Of the two, I’d probably choose the Kazakhstan-based oil and gas explorer if I were to add a high-risk, high-reward stock to my portfolio. Here’s why. 

Omega Diagnostics 

Omega announced today that it had tested its devices “on a large number of patient samples with the aim of optimising performance and deciding on suitable in-house manufacturing processes,” adding that it has now made three pilot batches of devices, “all of which have yielded comparable results and which demonstrate that Visitect CD4 is capable of meeting the company’s performance design goals in comparison to flow cytometry when tested on HIV positive patients.”

Although Omega remains “very confident of the prospective commercial success of Visitect CD4,” what this means is that it remains unclear whether Visitect CD4 will ever generate any revenues.

In October last year, management warned that annual results would disappoint investors due to manufacturing problems with its benchmark HIV test kit, news of which pushed the stock down to 16p from about 19p in a single trading session. Now the shares trade at about 24p, but key to value creation is the commercialisation of Visitect CD4, which may or may not make it to the market this year or next. 

While Omega said that its “internal investigation phase is now complete as planned,” its stock remains highly illiquid, and value investors may need more concrete news to budge. Its market cap is only £24m, which implies net earnings multiples of 27x and 24x for 2015 and 2016, respectively. Also based on trading multiples for forward sales, the stock is not incredibly expensive, true — but a strong sterling could hurt profits over the next 24 months.


Today’s operational update is important for two reasons. 

Firstly, it shows that Roxi has options, as it fetches more cash than it had hoped from the sale of the Galaz contract area in Kazakhstan. The acquirer is a consortium led by Xinjiang Zhundong Petroleum Technology, which will pay up following an increase in the price of brent crude — “the aggregate consideration will be $100m and Roxi’s effective consideration has increased to $23m,” from $20m, which is not small change for a company with negative operating cash flow and normalised capex above $10m annually. The funds from the Galaz disposal will be used to fund the development of its flagship BNG assets. 

Secondly, “in April 2015, Roxi announced the agreement to issue new shares at an effective price of 18p per shares to BOCO (…) to raise $20m,” but in light of “the imminent completion of the sale of Galaz and difficulties in receiving timely payment, Roxi has informed BOCO it is not continuing  with this subscription and has terminated discussions with them.”

Good news on this front, too. With a market cap of £122m, Roxi trades around 16.3p a share, some 36 % below its 52-week high of 25.5p as of 1 September 2014. It’s a bet worth taking, I’d argue. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After falling 9% in 6 weeks, is this FTSE 100 stock now in bargain territory?

The BAE Systems share price hit a 52-week high on 3 June. Six weeks later, it’s down nearly 10%. Is…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

I love the look of Entain shares, potentially 47% undervalued

Many FTSE 100 companies have been on a tear in 2024, but with Entain shares down nearly 50%, I think…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Could Aviva shares reach £5.84 in the next 12 months?

Some analysts think Aviva shares could soar nearly 19% in the next year. This Fool takes a closer look to…

Read more »

Investing Articles

I’m looking at a once-in-a-decade chance to buy dirt-cheap FTSE dividend shares

Harvey Jones says FTSE 100 dividend shares have been showing signs of life lately but they're still cheap and there's…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

If I’d put £10k in BAE Systems shares 10 years ago, here’s what I’d have now

BAE Systems shares have been on fire over the last decade. But just how much would a £10k investment back…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

My favourite S&P 500 stock is still potentially 52% undervalued

The S&P 500 is where many investors look for the next opportunity, but one of my favourites might just be…

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

Here’s why I’m watching the Glencore share price

The mining sector has always been volatile, but with some recent strategic moves, I'm watching the Glencore share price even…

Read more »

Young black female footballer training on stadium pitch
Investing Articles

My JD Sports Fashion share price prediction for the second half of 2024

The JD Sports Fashion share price hasn't yet recovered from January’s slump. So will the retailer's stock bounce back in…

Read more »